Dr. Michael Schenker
Claim this profileGSK Investigational Site
Area of expertise
Lung Cancer
Michael Schenker has run 8 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Michael Schenker has run 7 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Clinical Trials Michael Schenker is currently running
Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib
for Breast Cancer
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting
2 awards
Phase 3
12 criteria
LY3537982 + Immunotherapy/Chemotherapy
for Non-Small Cell Lung Cancer
This trial is testing a new drug, LY3537982, combined with standard treatments for patients with advanced lung cancer that have a specific genetic mutation. The goal is to see if this combination works better than the usual treatments alone.
Recruiting
1 award
Phase 3
14 criteria
More about Michael Schenker
Clinical Trial Related
2 years of experience running clinical trials · Led 25 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Michael Schenker has experience with
- Dostarlimab
- Abemaciclib
- Docetaxel
- Nivolumab
- Cisplatin
- Carboplatin
Breakdown of trials Michael Schenker has run
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Schenker specialize in?
Michael Schenker focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Michael Schenker currently recruiting for clinical trials?
Yes, Michael Schenker is currently recruiting for 7 clinical trials in Craiova Dolj. If you're interested in participating, you should apply.
Are there any treatments that Michael Schenker has studied deeply?
Yes, Michael Schenker has studied treatments such as Dostarlimab, Abemaciclib, Docetaxel.
What is the best way to schedule an appointment with Michael Schenker?
Apply for one of the trials that Michael Schenker is conducting.
What is the office address of Michael Schenker?
The office of Michael Schenker is located at: Centrul de Oncologie Sf. Nectarie, Craiova, Dolj 200542 Romania. This is the address for their practice at the Centrul de Oncologie Sf. Nectarie.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.